G1 Therapeutics, Inc. (GTHX) is Down 3.95% Today: Let’s Zoom In A Bit

G1 Therapeutics, Inc. (NASDAQ:GTHX) could be one of the worst stocks that investors may not want to consider for their portfolio today as the company shares are trading 3.95% or 0.93 points down from last closing price of $23.52, reaching $22.59 at last check. Any clue why there is so much of action in the GTHX stock? The share price is losing for the fifth day in a row and has dropped in 2 of the last 5 days and is down -34.25% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -465,299 shares, and in total 110801 shares valued at $2.503 million were seen changing hands compared with 576100 shares valued at $13.55 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the GTHX stock is near its bottom.

G1 Therapeutics, Inc. (GTHX) shares have notched a 3-month decline of about -34.25%, but has still advanced 22.82% year to date. By comparison, the stock sank -38.01% over the past 12 months, while it jumped 13.4% over the 1 month. The company’s market cap is around $856.13M, with its short interest ratio standing at 12.94%.

In the current trading session for GTHX, the stock witnessed two major price actions, it rose to a high of $23.59 and was down as much as $22.34 at one point. The high recorded is very low when compared to their 52-week high which is $13.87. The 52-week high is now at -46.05 distance from current price. Their recent low of $41.8 represents a 62.58% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for GTHX is $66.5, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

GTHX‘s last price was down -6.46% as compared to the average trading price of 50 days recorded at $24.15 while enlarging the period to 200 trading days, the average closing price was $25.42. At present, there are 36.4 million in the total number of common shares owned by the public and among those 33.44 million shares have been available to trade. The percentage of shares being held by the company management was 17.81% while institutions stake was 97%. The company has generated negative returns on equity over the last 12 months (-34.3%). It managed to keep its gross profit margin at 0% over the past 12 months.

When assessing the full upside of the GTHX stock, there is another set of technicals that should be looked into and considered. Its 0.17% gain from moving average of $22.55 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of G1 Therapeutics, Inc. — 6 analysts rate the stock as a buy with another 1 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $62.6 on shares of G1 Therapeutics, Inc. (NASDAQ:GTHX), which corresponds to 177.61% upside potential than its current market price of $22.59 and implies potential despite the recent drop in the price. However, their current target price has fallen from $62.6 a month ago and is down handily from the consensus target of $66.67 a quarter ago.

Let’s briefly check the hedge fund interest towards GTHX stock. Alps Advisors Inc. trimmed position in the company after it dumped -4.5% or 78,379 shares of its common stock. The hedge fund now owns 74,852 shares worth $1,690,907, SEC documents show. California Public Employees Retirement System shored up assets in the stock as 31501.88 shares have been purchased, increasing its stake by 113.2% to 67,162 shares which are currently valued at $1,517,190. In addition, Rhumbline Advisers recently reported that it now owns 45,839 shares making a total of $1,035,503 based on the recent price. This refelects a change of 4% in their ownership.